Pharmaceuticals, Biotechnology and Life Sciences
Euronext listed biopharma company Probiodrug AG, a clinical stage developer therapeutics to treat Alzheimer’s disease (AD), has announced that results…
Probiodrug, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), and the Dutch biotech company Crossbeta Biosciences have extended their strategic…
Probiodrug, a Germany-based biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD) and other neurodegenerative disorders, has reported that Last Patient’s Last Visit (LPLV) occurred on 05 April 2017 in the currently running Phase 2a SAPHIR study investigating the QC-inhibitor PQ912 in patients with early AD.
Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing therapeutic solutions to treat Alzheimer’s disease, has finished the third quarter 2016…